Molecular marker for type 2 diabetes mellitus and application of molecular marker

Since type 2 diabetes mellitus is often insidious onset and asymptomatic in the early stage, existing clinical diagnosis basis, such as blood sugar, glucose tolerance, and "three more and one less" symptoms lack sensitivity and specificity, and clinical diagnosis is usually 4-7 years later...

Full description

Saved in:
Bibliographic Details
Main Authors KONG XIANG, HUA QIANG, WAN SHUJUN, LYU KUN
Format Patent
LanguageChinese
English
Published 06.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Since type 2 diabetes mellitus is often insidious onset and asymptomatic in the early stage, existing clinical diagnosis basis, such as blood sugar, glucose tolerance, and "three more and one less" symptoms lack sensitivity and specificity, and clinical diagnosis is usually 4-7 years later than actual clinical onset. Therefore, finding a new clinical diagnosis marker for type 2 diabetes mellitus and exploring pathogenesis of type 2 diabetes mellitus are urgent problems to be solved in the field. The invention discloses an extrachromosomal circular DNA, which is named as SORBS1cycle, and has a nucleotide sequence shown as SEQ ID NO: 1. The invention discloses an application of the extrachromosomal circular DNA in preparation of a product for diagnosing or treating type 2 diabetes mellitus. According to the invention, potential target genes of eccDNAs differentially expressed by T2DM and molecular mechanism of action are analyzed through comparative experiments and correlation analysis, providing new ideas for
Bibliography:Application Number: CN202110462996